• PDF / 169,715 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 12 Downloads / 154 Views

DOWNLOAD

REPORT

---

1 XS

Neutropenia and fracture: 3 case reports In a retrospective study of 94 patients, 3 patients [ages and sexes not stated] were described, who developed neutropenia during treatment with radium-223-chloride (1 patient) and fracture (2 patients) following a concomitant administration of abiraterone acetate, prednisone and radium-223-chloride for metastatic castration-resistant prostate cancer (mCRPC) [not all routes and durations of treatments to reaction onsets stated; outcomes not stated]. The patients, who had mCRPC, received two anti-cancer agents at standard doses: oral abiraterone acetate 1000 mg/day plus prednisone 10 mg/day. As the patients progressed on the anti-cancer agents, they started receiving treatment with IV radium-223-chloride 55 kBq/kg of body weight every 4 weeks. However, one patient developed grade 3 neutropenia as a side-effect of radium-223-chloride. Two patients developed fractures at metastatic sites; one during the course of radium-223-chloride and other 1 month following the discontinuation of radium-223-chloride. It was assumed that the increased risk of fractures associated with the abiraterone acetate/radium-223-chloride combination was because of the synergistic inhibitory effect of abiraterone acetate and prednisone on osteoblasts, and the osteoclastogenic effects of androgen deprivation therapy and radium-223-chloride. Caffo O, et al. Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223. European Journal of Nuclear Medicine and Molecular Imaging 47: 2633-2638, No. 11, Oct 2020. Available from: URL: http://doi.org/10.1007/ 803516376 s00259-020-04796-w

0114-9954/20/1831-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 21 Nov 2020 No. 1831